{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:28:48Z","timestamp":1793320128697,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"research funds division of rheumatology, university hospital bern","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the effect of ACE inhibitors (ACEi) on the incidence of scleroderma renal crisis (SRC) when given prior to SRC in the prospectively collected cohort from the European Scleroderma Trial and Research Group (EUSTAR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SSc patients without prior SRC and at least one follow-up visit were included and analyzed regarding SRC, arterial hypertension, and medication focusing on antihypertensive medication and glucocorticoids (GC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 14,524 patients in the database, we identified 7648 patients with at least one follow-up. In 27,450 person-years (py), 102 patients developed SRC representing an incidence of 3.72 (3.06\u20134.51) per 1000 py. In a multivariable time-to-event analysis adjusted for age, sex, disease severity, and onset, 88 of 6521 patients developed SRC. The use of ACEi displayed an increased risk for the development of SRC with a hazard ratio (HR) of 2.55 (95% confidence interval (CI) 1.65\u20133.95). Adjusting for arterial hypertension resulted in a HR of 2.04 (95%CI 1.29\u20133.24). There was no evidence for an interaction of ACEi and arterial hypertension (HR 0.83, 95%CI 0.32\u20132.13,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.69). Calcium channel blockers (CCB), angiotensin receptor blockers (ARB), endothelin receptor antagonists, and GC\u2014mostly in daily dosages below 15\u2009mg of prednisolone\u2014did not influence the hazard for SRC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ACEi in SSc patients with concomitant arterial hypertension display an independent risk factor for the development of SRC but are still first choice in SRC treatment. ARBs might be a safe alternative, yet the overall safety of alternative antihypertensive drugs in SSc patients needs to be further studied.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-020-2141-2","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T09:02:46Z","timestamp":1585040566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis\u2014a EUSTAR analysis"],"prefix":"10.1186","volume":"22","author":[{"name":"on behalf of EUSTAR collaborators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"B\u00fctikofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre A.","family":"Varisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Kowal-Bielecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"Villiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4194-9146","authenticated-orcid":false,"given":"S.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"issue":"5","key":"2141_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","volume":"113","author":"VD Steen","year":"1990","unstructured":"Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113(5):352\u20137.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2141_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","volume":"43","author":"M Hudson","year":"2014","unstructured":"Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D. International scleroderma renal crisis study I. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the international scleroderma renal crisis survey. Semin Arthritis Rheum. 2014;43(5):666\u201372.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2141_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/rheumatology\/ker271","volume":"51","author":"L Guillevin","year":"2012","unstructured":"Guillevin L, Berezne A, Seror R, Teixeira L, Pourrat J, Mahr A, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology. 2012;51(3):460\u20137.","journal-title":"Rheumatology."},{"issue":"2","key":"2141_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12016-009-8191-5","volume":"40","author":"L Mouthon","year":"2011","unstructured":"Mouthon L, Berezne A, Bussone G, Noel LH, Villiger PM, Guillevin L. Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. Clin Rev Allergy Immunol. 2011;40(2):84\u201391.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"2141_CR5","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.amjmed.2018.02.031","volume":"131","author":"M Khalaf","year":"2018","unstructured":"Khalaf M, Chowdhary S, Elias PS, Castell D. Distal esophageal spasm: a review. Am J Med. 2018;131(9):1034\u201340.","journal-title":"Am J Med"},{"issue":"5","key":"2141_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s100670050132","volume":"18","author":"H Kobayashi","year":"1999","unstructured":"Kobayashi H, Nishimaki T, Kaise S, Suzuki T, Watanabe K, Kasukawa R, et al. Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol. 1999;18(5):425\u20137.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"2141_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/qjmed\/hct111","volume":"106","author":"H Penn","year":"2013","unstructured":"Penn H, Quillinan N, Khan K, Chakravarty K, Ong VH, Burns A, et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM. 2013;106(9):839\u201348.","journal-title":"QJM"},{"issue":"10103","key":"2141_CR8","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685\u201399.","journal-title":"Lancet."},{"issue":"1","key":"2141_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-018-1517-z","volume":"20","author":"S Adler","year":"2018","unstructured":"Adler S, Huscher D, Siegert E, Allanore Y, Czirjak L, DelGaldo F, et al. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Therapy. 2018;20(1):17.","journal-title":"Arthritis Res Therapy"},{"issue":"4","key":"2141_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.autrev.2017.02.012","volume":"16","author":"S Hoa","year":"2017","unstructured":"Hoa S, Stern EP, Denton CP, Hudson M, Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group Investigators of the Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group. Towards developing criteria for scleroderma renal crisis: a scoping review. Autoimmun Rev. 2017;16(4):407\u201315.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"2141_CR11","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/art.40809","volume":"71","author":"EM Butler","year":"2019","unstructured":"Butler EM, Baron M, Fogo AB, Frech T, Ghossein C, Hachulla E, et al. Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology. Arthritis Rheumatol. 2019;71(6):964\u201371.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2141_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","volume":"75","author":"SR Cole","year":"2004","unstructured":"Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Prog Biomed. 2004;75(1):45\u20139.","journal-title":"Comput Methods Prog Biomed"},{"key":"2141_CR13","doi-asserted-by":"crossref","unstructured":"Gliddon AE, Dore CJ, Black CM, McHugh N, Moots R, Denton CP, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud\u2019s phenomenon: a randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007;56(11):3837\u201346.","DOI":"10.1002\/art.22965"},{"issue":"5","key":"2141_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0002-9343(84)90986-0","volume":"76","author":"VD Steen","year":"1984","unstructured":"Steen VD, Medsger TA Jr, Osial TA Jr, Ziegler GL, Shapiro AP, Rodnan GP. Factorspredicting development of renal involvement in progressive systemic sclerosis. Am J Med. 1984;76(5):779\u201386.","journal-title":"Am J Med"},{"issue":"7","key":"2141_CR15","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3899\/jrheum.151353","volume":"43","author":"M Turk","year":"2016","unstructured":"Turk M, Pope JE. The frequency of scleroderma renal crisis over time: a metaanalysis. J Rheumatol. 2016;43(7):1350\u20135.","journal-title":"J Rheumatol"},{"issue":"6","key":"2141_CR16","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66(6):754\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2141_CR17","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/rheumatology\/kep464","volume":"49","author":"PP Khanna","year":"2010","unstructured":"Khanna PP, Furst DE, Clements PJ, Maranian P, Indulkar L, Khanna D, et al. Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology (Oxford). 2010;49(5):955\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2141_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/annrheumdis-2014-205295","volume":"75","author":"J Avouac","year":"2016","unstructured":"Avouac J, Walker UA, Hachulla E, Riemekasten G, Cuomo G, Carreira PE, et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016;75(1):103\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2141_CR19","doi-asserted-by":"crossref","unstructured":"Steen VD, Medsger TA, Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41(9):1613\u20139.","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O"},{"issue":"2","key":"2141_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrneph.2009.228","volume":"6","author":"RW Schrier","year":"2010","unstructured":"Schrier RW. Aldosterone \u2018escape\u2019 vs \u2018breakthrough\u2019. Nat Rev Nephrol. 2010;6(2):61.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2141_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jash.2012.07.003","volume":"6","author":"AS Bomback","year":"2012","unstructured":"Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. J Am Soc Hypertension. 2012;6(5):338\u201345.","journal-title":"J Am Soc Hypertension"},{"issue":"4","key":"2141_CR22","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.ajkd.2009.02.015","volume":"54","author":"N Dhaun","year":"2009","unstructured":"Dhaun N, MacIntyre IM, Bellamy CO, Kluth DC. Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis. 2009;54(4):726\u201331.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 106(4)","key":"2141_CR23","first-page":"56","volume":"35","author":"G Li","year":"2017","unstructured":"Li G, Adachi JD, Cheng J, Thabane L, Hudson M, Fritzler MJ, et al. Relationship between calcium channel blockers and skin fibrosis in patients with systemic sclerosis. Clin Exper Rheumatol. 2017;35(Suppl 106(4)):56\u201360.","journal-title":"Clin Exper Rheumatol"},{"issue":"1","key":"2141_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.humpath.2010.05.018","volume":"42","author":"L Mouthon","year":"2011","unstructured":"Mouthon L, Mehrenberger M, Teixeira L, Fakhouri F, Berezne A, Guillevin L, et al. Endothelin-1 expression in scleroderma renal crisis. Hum Pathol. 2011;42(1):95\u2013102.","journal-title":"Hum Pathol"},{"issue":"2","key":"2141_CR25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1053\/j.ajkd.2013.04.016","volume":"62","author":"H Izzedine","year":"2013","unstructured":"Izzedine H, Rouvier P, Deray G. Endothelin receptor antagonism-based treatment for scleroderma renal crisis. Am J Kidney Dis. 2013;62(2):394\u20135.","journal-title":"Am J Kidney Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-2141-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-020-2141-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-2141-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T20:35:44Z","timestamp":1616531744000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-2141-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2141"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-2141-2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737631531.793573408","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"17 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As a rule of EUSTAR, each participating center is obliged to obtain ethics approval by their respective local ethics committee prior to data acquisition and transmission.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}